IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application	n of: KUJUNDZIC, et al.	Group Art Unit: 1623							
Serial No.:	10/534,628	Examiner: Peselev, Elli							
File Date:	October 5, 2005	Attorney Docket No: PLP480USW							
For: Substituted 9a-N-(N'-(Sulfonyl)Phenylcarbamoyl) Derivatives of 9-Deoxo-9-Dihydro-9a-aza-9a-Homoerythromycin A and 5-O-Desosaminyl-9-Deoxo-9-Dihydro-9a-aza-9a-Homoerythronolide A									
Director of the P.O. Box 1450 Alexandria, VA	U.S. Patent and Trademark Offic	е							
s	UPPLEMENTAL INFORMAT	TION DISCLOSURE STATEMENT							
Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97									
[X]Copies of the references are enclosed: Foreign Patent Documents [] Copies of the references were submitted in parent application									
								A. []	months of the filing date of the abo
OR [X]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).								
of t fort	he filing date of the above application in § 1.491 of an international application on the merits, whichever event of a final action under § 1.113 or	transmitted herewith is being filed after three months ion or the date of entry into the national stage as set lication or after the mailing date of the first Office occurred last, but before the mailing date of either: 1.311, whichever occurs first.							
[]Applicant hereby certifies that each item of information contained in this Information Disclosur Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.									
	licant elects the option to pay the fe rmation Disclosure Statement under	e set forth in 37 CFR 1.17(p) for submission of an r § 1.97(c) (\$180.00).							
unc pay	der § 1.113, or a notice of allowance	transmitted herewith is being filed after a final action a under § 1.311, whichever occurs first, but before the ed is a copy of the International Search Report which							

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith. []
- [x] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Attorney for Applicants Registration No. 39,337

Date: Monther 8, W. 7. GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2192 Facsimile: (919) 483-7988

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10534628	
Filing Date		2005-10-05	
First Named Inventor	KUJUNDZIC, et al.		
Art Unit		1623	
Examiner Name	Peselev, Elli		
Attorney Docket Number		PLP480USw	

CERTIFICATION STATEMENT									
Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):									
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).								
OR	•								
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).								
X	───────────────────────────────────								
	Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.								
	None								
		=	TURE						
A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.									
Sign	ature	Farin Line	Date (YYYY-MM-DD)	2007-11-08					
Name/Print		Karen L Prus	Registration Number	39,337					
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed									
requ	application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND								

FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,

VA 22313-1450.